Kymera Therapeutics, Inc. (KYMR)Healthcare | Biotechnology | Watertown, United States | NasdaqGM
87.71 USD
+1.57
(1.823%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 86.00 -1.71 (-1.710%) ⇩ (April 17, 2026, 6:28 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 8:03 p.m. EDT
Kymera Therapeutics presents a classic 'high-risk, high-reward' narrative where technical momentum and catalyst-driven sentiment (Fast Track designation) are outpacing fundamental reality. While the stock is currently rallying on strong analyst consensus and options positioning for a 115-140 price target, the company remains unprofitable with negative revenue growth and no dividend history. The insider selling is a persistent red flag that contradicts the 'Strong Buy' analyst ratings, creating a precarious setup where a short-term squeeze is likely, but the long-term hold requires navigating a value trap scenario until clinical data proves the business model viable. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.083480 |
| AutoARIMA | 0.138509 |
| AutoETS | 0.140549 |
| MSTL | 0.148735 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.43 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.630 |
| Excess Kurtosis | -0.11 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.207 |
| Revenue per Share | 0.464 |
| Market Cap | 7,160,854,016 |
| Forward P/E | -21.88 |
| Beta | 2.29 |
| Website | https://www.kymeratx.com |
As of April 18, 2026, 8:03 p.m. EDT: Speculators are heavily positioning for a short-term breakout with significant call volume concentrated at the 90 and 115 strikes for mid-to-longer term expirations (May, Aug, Dec), while near-term (April) options show a balanced but slightly call-heavy flow with high Open Interest at the 90 strike. Notably, the May expiration calls show 85% of OI in OTM strikes, suggesting a bullish tailwind expectation for the May 2026 period. Conversely, put OI is heavily skewed toward lower strikes (70-80) for the 2027 expiry, indicating long-term hedging against downside rather than immediate bearish pressure. The high IV on short-dated puts (1.88 atm) vs calls (0.72 atm) suggests fear of immediate volatility, but the volume in far-dated calls signals a belief in sustained upward momentum following the FDA Fast Track designation.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.2293816 |
| Address1 | 500 North Beacon Street |
| Address2 | 4th Floor |
| All Time High | 103.0 |
| All Time Low | 9.6 |
| Ask | 87.91 |
| Ask Size | 1 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 478,400 |
| Average Daily Volume3 Month | 728,251 |
| Average Volume | 728,251 |
| Average Volume10Days | 478,400 |
| Beta | 2.289 |
| Bid | 87.47 |
| Bid Size | 1 |
| Board Risk | 8 |
| Book Value | 19.424 |
| City | Watertown |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 87.71 |
| Current Ratio | 10.47 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 88.45 |
| Day Low | 87.055 |
| Debt To Equity | 5.207 |
| Display Name | Kymera Therapeutics |
| Earnings Call Timestamp End | 1,772,112,600 |
| Earnings Call Timestamp Start | 1,772,112,600 |
| Earnings Timestamp | 1,772,112,600 |
| Earnings Timestamp End | 1,778,243,400 |
| Earnings Timestamp Start | 1,778,243,400 |
| Ebitda | -338,831,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -18.873 |
| Enterprise To Revenue | 163.088 |
| Enterprise Value | 6,394,830,336 |
| Eps Current Year | -3.59695 |
| Eps Forward | -4.00795 |
| Eps Trailing Twelve Months | -3.69 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 83.8117 |
| Fifty Day Average Change | 3.8983002 |
| Fifty Day Average Change Percent | 0.0465126 |
| Fifty Two Week Change Percent | 222.93816 |
| Fifty Two Week High | 103.0 |
| Fifty Two Week High Change | -15.290001 |
| Fifty Two Week High Change Percent | -0.1484466 |
| Fifty Two Week Low | 25.495 |
| Fifty Two Week Low Change | 62.214996 |
| Fifty Two Week Low Change Percent | 2.440282 |
| Fifty Two Week Range | 25.495 - 103.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,598,016,600,000 |
| Float Shares | 54,428,535 |
| Forward Eps | -4.00795 |
| Forward P E | -21.884007 |
| Free Cashflow | -136,041,248 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 238 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -277,356,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02204 |
| Held Percent Institutions | 1.10538 |
| Implied Shares Outstanding | 81,642,394 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-08-21 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts. |
| Long Name | Kymera Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 7,160,854,016 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_542085131 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -311,351,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 7,156,772,258 |
| Number Of Analyst Opinions | 21 |
| Open | 87.75 |
| Operating Cashflow | -232,891,008 |
| Operating Margins | -34.1101 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 857 285 5300 |
| Post Market Change | -1.7099991 |
| Post Market Change Percent | -1.9496056 |
| Post Market Price | 86.0 |
| Post Market Time | 1,776,464,895 |
| Previous Close | 86.14 |
| Price Eps Current Year | -24.384548 |
| Price Hint | 2 |
| Price To Book | 4.5155478 |
| Price To Sales Trailing12 Months | 182.6236 |
| Profit Margins | 0.0 |
| Quick Ratio | 10.194 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.30435 |
| Region | US |
| Regular Market Change | 1.57 |
| Regular Market Change Percent | 1.82261 |
| Regular Market Day High | 88.45 |
| Regular Market Day Low | 87.055 |
| Regular Market Day Range | 87.055 - 88.45 |
| Regular Market Open | 87.75 |
| Regular Market Previous Close | 86.14 |
| Regular Market Price | 87.71 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 563,495 |
| Return On Assets | -0.15875 |
| Return On Equity | -0.25782 |
| Revenue Growth | -0.612 |
| Revenue Per Share | 0.464 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 81,642,394 |
| Shares Percent Shares Out | 0.1274 |
| Shares Short | 10,402,722 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 10,275,249 |
| Short Name | Kymera Therapeutics, Inc. |
| Short Percent Of Float | 0.1528 |
| Short Ratio | 14.46 |
| Source Interval | 15 |
| State | MA |
| Symbol | KYMR |
| Target High Price | 140.0 |
| Target Low Price | 91.0 |
| Target Mean Price | 119.14286 |
| Target Median Price | 120.0 |
| Total Cash | 848,275,968 |
| Total Cash Per Share | 10.39 |
| Total Debt | 82,252,000 |
| Total Revenue | 39,211,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.69 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 65.1783 |
| Two Hundred Day Average Change | 22.5317 |
| Two Hundred Day Average Change Percent | 0.3456933 |
| Type Disp | Equity |
| Volume | 563,495 |
| Website | https://www.kymeratx.com |
| Zip | 2,472 |